Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | IDUA | P35475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13471588 | 1.00 | FUCA1 (0.37) | FUCA1CA9CA12CA2IDUA | |
| SCHEMBL12899923 | 0.98 | FUCA1 (0.34) | FUCA1CA9CA12CA2 | |
| SCHEMBL27395773 | 0.79 | — | — | |
| SCHEMBL12015083 | 0.79 | CA12 (0.33) | CA9CA12CA2IDUA | |
| SCHEMBL13471605 | 0.79 | CA12 (0.33) | CA9CA12CA2IDUA | |
| SCHEMBL16620337 | 0.79 | FUCA1 (0.37) | FUCA1CA9CA12CA2 | |
| SCHEMBL9914020 | 0.77 | FUCA1 (0.40) | FUCA1CA9CA12CA2IDUA | |
| SCHEMBL9915194 | 0.77 | FUCA1 (0.40) | FUCA1CA9CA12CA2IDUA | |
| SCHEMBL9914017 | 0.77 | FUCA1 (0.40) | FUCA1CA9CA12CA2IDUA | |
| SCHEMBL14025396 | 0.77 | FUCA1 (0.40) | FUCA1CA9CA12CA2IDUA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-8198419-B2 | Glycorandomization and production of novel erythromycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-7348309-B2 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | NMT2, NMT1, NAMPT | FUCA1 263/4885CA9 2500/4885CA12 1699/4885 |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | FUCA1 305/4885CA9 2663/4885CA12 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.